Spending like a bigger company on purpose: current results carry the cost of an expansion aimed at demand management say
The model's full reasoning — Q2 2022 call → NOThe question asks whether management acknowledges that current results are being weighed down by an expansion already undertaken, and whether they justify it by pointing to demand that is already real. Let me analyze the transcript: 1. Expansion already underway and visibly costing something now: - The company has been making acquisitions (ValueHealth, de novos, etc.) - They deployed $135 million on 10 ASC transactions year-to-date - They acquired 4 in-process de novos from ValueHealth - They have been recruiting physicians (250+ in first half) - They mention robotics investments But do they acknowledge that this expansion is depressing, straining, or weighing on current period profitability, margins, cash, or efficiency? Looking at the transcript: - They discuss M&A deployment but don't say it's weighing on current results - They discuss physician recruiting but don't say it's costing current profitability - They discuss de novos but don't say these are dragging on results - They discuss inflationary pressures but attribute them to external factors, not their own expansion The management discusses: - Inflationary pressures on labor and supply costs - attributed to external environment - COVID variants - external - They say they've managed costs "in line with our expectation and to pre-pandemic levels" They don't seem to acknowledge that their expansion is visibly costing them something now. They talk about deploying capital, but not about how that deployment is depressing current results. 2. Justification by demand already real: - They talk about physician recruiting bringing cases - They talk about joint replacements up 32% - They talk about cardiac procedures up 9% - They talk about new recruits bringing more cases But this seems more like describing growth they're already achieving, not justifying a burden. The key question is whether management presents a coherent picture of: "We're building something that costs us now, but the demand is already here." Looking more carefully: - They mention de novos take 18+ months to syndicate and build - They acquired 4 in-process de novos - They mention "we are preparing for the next wave in procedures that we expect to migrate to outpatient settings" But they don't say these de novos are weighing on current results.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| PUMP | ProPetro Holding Corp. | Q4 2023 | 2024-02-21 | C+ |
| PTLO | Portillo's Inc. | Q2 2023 | 2023-08-05 | B |
| AFL | Aflac Incorporated | Q2 2023 | 2023-08-02 | C+ |
| KE | Kimball Electronics, Inc. | Q3 2023 | 2023-05-06 | C+ |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| CHE | Chemed Corporation | Q3 2022 | 2022-11-01 | B+ |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| WD | Walker & Dunlop, Inc. | Q2 2022 | 2022-08-09 | C+ |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| FLYW | Flywire Corporation | Q1 2022 | 2022-05-14 | B+ |
| HLIO | Helios Technologies, Inc. | Q1 2022 | 2022-05-10 | C |
| IRTC | iRhythm Technologies, Inc. | Q1 2022 | 2022-05-07 | C+ |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
| LMAT | LeMaitre Vascular, Inc. | Q3 2021 | 2021-10-29 | C+ |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| JBT | John Bean Technologies Corporation | Q2 2018 | 2018-07-26 | B |
| CP | Canadian Pacific Railway Limited | Q2 2018 | 2018-07-19 | B+ |
| AOSL | Alpha and Omega Semiconductor Limited | Q2 2018 | 2018-02-07 | B |
| IR | Ingersoll-Rand Plc | Q3 2017 | 2017-10-25 | B |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
SIBN · Q3 2022 → YESThe question is: Does management acknowledge that the company's CURRENT reported results are being visibly weighed down by the cost of an expansion the company has ALREADY undertaken — spending, hirin...YES Management explicitly describes the expansion as already underway and costing the company now: investments in sales force (85 territory managers + 72 specialists), new products (iFuse-TORQ, iFuse-Bedrock Granite), instrument trays, inventory, and R&D that are driving higher depreciation, freight, and product costs 84% gross margin (down low-single digits from these factors). Anshul confirms “we’ve made a substantial amount of investment whether it’s in TORQ trays or Granite trays or TORQ implants” and “this is going to lead to elevated depreciation,” while Laura notes the build supports “strong new product demand.
FLYW · Q1 2022 → YESThe question is: Does management acknowledge that the company's CURRENT reported results are being visibly weighed down by the cost of an expansion the company has ALREADY undertaken, AND justify carr...YES The transcript shows management explicitly linking the current EBITDA decline to the hiring expansion already completed ("increased the number of FlyMates by over 50% during the past year" and "added over 100 new FlyMates within the sales, marketing and product functions"), while framing the spending as a deliberate, ongoing 2022 investment plan that is already delivering observable results through record client adds (130), pipeline growth, and strong ARR signings.
EVGO · Q2 2022 → YESThe question is: Does management acknowledge that the company's CURRENT reported results are being visibly weighed down by the cost of an expansion the company has ALREADY undertaken, AND justify carr...YES Management describes concrete expansion already underway—170 stalls placed in Q2, total stalls at 2,397 with 460 under construction, pipeline at 3,669, CapEx jumped to $44 million to accelerate deployment, and G&A ramping personnel to support growth—while directly tying the resulting negative adjusted EBITDA of -$19.8 million to that deliberate build-out.